Disease-free survival after resection of lung metastases in patients with breast cancer

Ludwig, Corinna; Stoelben, Erich; Hasse, J

doi:10.1016/s0748-7983(03)00074-x

Cited by 43 publications

(40 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the exception of one case series, all other studies included patients with bilateral metastasis [2][3][4][5][7][8][9][10][11]. On the basis of survival data presented here, breast cancer patients with pulmonary metastasis would seem to benefit from metastasectomy both when disease-free interval is less than 12 months and in the case of bilateral lung metastases.…”

Section: Lung Metastasis Surgery Recommendationsmentioning

confidence: 91%

“…The literature search performed on 15 February 2017 had 2426 hits in MEDLINE and found one review article in the Cochrane library. After step-wise appraisal 11 studies where identified each with at least 20 patients having had lung metastasectomy following primary tumour treatment with curative intent [2][3][4][5][6][7][8][9][10][11][12].…”

Section: Methodsmentioning

confidence: 99%

“…Ten of the reviewed studies were case series, together reporting on over 971 patients with treated breast carcinoma and pulmonary metastasectomy [2][3][4][5][6][7][8][9][10][11]. Operations were performed between 1960 and 2007.…”

Section: Methodsmentioning

confidence: 99%

“…Pulmonary metastasectomy resulted in a median post-metastasectomy survival of 32 to 96.6 months (▶ Table 2) [2][3][4][5][8][9][10][11]. Five-year survival rates were between 30.8 and 54.4 %, while 10-year survival rates were between 18 and 51 % [2][3][4][5][6][7][8][9][10]. One meta-analysis from the year 2015 analysed the survival prognosis of patients with breast carcinoma after lung metastasis surgery quantitatively [12].…”

Section: Survival After Metastasis Surgerymentioning

confidence: 99%

“…Prognostic factors (based on univariate analyses) Friedel et al [2] Ludwig et al [3] Planchard et al [4] Tanaka et al [5] Rena et al [6] Chen et al [7] Welter et al [8] Kycler et al [9] Yoshimoto et al [10] Meimarakis et al [ …”

Section: Lung Metastasis Surgery Recommendationsmentioning

confidence: 99%

See 4 more Smart Citations

Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma

Macherey

Mallmann

Malter

et al. 2017

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

ABSTR AC TBreast carcinoma with pulmonary metastasis can be treated locally or systemically. Following primary tumour resection patients with isolated, completely resectable pulmonary nodules and definite functional operability can be offered lung metastasis resection. Following metastasectomy a median survival of 32 to 96.6 months can be achieved with corresponding five-year survival rates between 30.8 and 54.4 %. The procedure is associated with a mortality rate of 0 to 3 %. The most important independent prognostic factor for longterm survival is complete resection of all lung lesions. The configuration and pattern of metastasis as well as disease-free interval, hormone and HER2/neu receptor status also appear to influence prognosis, but are of lesser importance. Intrapulmonary recurrence of metastases may, after careful selection on a case-by-case basis, also be treated operatively. In some cases this is associated with a favourable long-term prognosis. Pulmonary metastasectomy should be the treatment of choice for selected patients with metastatic breast carcinoma. ZUSAMMENFASSUNG

show abstract

Section: Lung Metastasis Surgery Recommendationsmentioning

confidence: 91%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Survival After Metastasis Surgerymentioning

confidence: 99%

Section: Lung Metastasis Surgery Recommendationsmentioning

confidence: 99%

See 3 more Smart Citations

Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma

Macherey

Mallmann

Malter

et al. 2017

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

show abstract

Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy

Yhim

Han

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The aim of this study was to evaluate the clinical treatment outcomes of recurrent breast cancer with a limited number of isolated lung metastases, and to evaluate the role of pulmonary metastasectomy. METH-ODS: The authors consecutively enrolled 140 recurrent breast cancer patients with isolated lung metastasis from 1997 to 2007 in Seoul National University Hospital and retrospectively analyzed 45 patients who had <4 metastatic lesions. RESULTS: Fifteen patients had pulmonary metastasectomy followed by systemic treatment (pulmonary metastasectomy group), and 30 received systemic treatment alone (nonpulmonary metastasectomy group). The 3-year progression-free survival (PFS) and 4-year overall survival (OS) was significantly longer in the pulmonary metastasectomy group than in the nonpulmonary metastasectomy group (3-year PFS, 55.0% vs 4.5%, P < .001; 4-year OS, 82.1% vs 31.6%, P ¼ .001). In multivariate analysis, a disease-free interval (DFI) of <24 months (hazard ratio [HR], 4.53; 95% CI, 1.72-11.90), no pulmonary metastasectomy (HR, 9.52; 95% CI, 3.34-27.18) and biologic subtypes such as human epithelial growth factor receptor-2 positive (HR, 3.00; 95% CI, 1.04-8.64) and triple negative (HR, 3.92; 95% CI, 1.32-11.59) were independent prognostic factors for shorter PFS. CONCLUSIONS: The authors' results demonstrated that DFI and biologic subtypes of tumor are firm, independent, prognostic factors for survival, and pulmonary metastasectomy can be a reasonable treatment option in this population. Further prospective studies are warranted to evaluate the role of pulmonary metastasectomy. Cancer 2010;116:2890-901.

show abstract

Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China

Lan

Abudureheiyimu

Zhang

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

Evidence of an oligometastatic state in metastatic breast cancer (MBC) is relatively limited. The aim of our study was to investigate the clinical features and prognostic factors for extracranial oligometastatic breast cancer and to identify the best treatment approaches in this select population. Fifty postoperative inpatients diagnosed with extracranial oligometastatic breast cancer at the National Cancer Center in China between 2009 and 2014 were consecutively enrolled. Oligometastatic breast cancer was defined as MBC with three or fewer metastatic lesions confined to one organ; de novo Stage IV disease and local-regional recurrence were excluded. The median progression-free survival (PFS) and overall survival (OS) times were 15.2 and 78.9 months, respectively, and the 2-year PFS and 5-year OS rates were 40% and 58%, respectively. First-line treatment approach with standard systemic treatment + surgical resection for all metastatic lesions was an independent prognostic factor for prolonged PFS (hazard ratio = 0.32; 95% confidence interval [CI], 0.14-0.73; P = .006) and OS (hazard ratio = 0.35; 95% CI, 0.14-0.86; P = .022). Subgroup analysis showed that patients with a disease-free interval (DFI) ≥24 months, one metastatic lesion or the hormone receptor (HR) + subtype were more likely to get benefit from resection. Patients with oligometastatic breast cancer have a relatively good prognosis. Surgical resection for metastatic lesions could significantly improve PFS and OS. Further prospective research is warranted to confirm the results and to develop biomarkers for better patient selection.

show abstract

Disease-free survival after resection of lung metastases in patients with breast cancer

Cited by 43 publications

References 6 publications

Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma

Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma

Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy

Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China

Contact Info

Product

Resources

About